FindTrial
Sign In

The relationship between the decrease extent of TRAb and Graves Disease

The relationship between the decrease extent of TRAb and Graves Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048171
Enrollment
Unknown
Registered
2021-07-04
Start date
2021-07-11
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Disease

Interventions

Primary hyperthyroidism group:No
Refractory hyperthyroidism group:No

Sponsors

The Second Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Outpatients from outpatients clinics of the Endocrinology Unit of the Second Affiliated Hospital of Chongqing medical university from 2016 to 2020 using ATD treatment.

Exclusion criteria

Exclusion criteria: 1. Renal impairment (serum creatinine 120 µmol/l); 2. Other autoimmune diseases; 3. Patients who were converted to surgery or 131I treatment during the follow-up period; 4. Neoplasms.

Design outcomes

Primary

MeasureTime frame
level of Thyroid receptor antibodies;Body Mass Index;Age;—

Countries

China

Contacts

Public ContactLiu Dongfang

The Second Affiliated Hospital of Chongqing Medical University

448377705@qq.com+86 18623407751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026